ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EKF Ekf Diagnostics Holdings Plc

27.60
0.80 (2.99%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.80 2.99% 27.60 27.60 28.00 28.00 27.00 27.40 613,915 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.61 127.38M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 26.80p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £127.38 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of -12.61.

Ekf Diagnostics Share Discussion Threads

Showing 2401 to 2424 of 4850 messages
Chat Pages: Latest  98  97  96  95  94  93  92  91  90  89  88  87  Older
DateSubjectAuthorDiscuss
04/11/2020
07:46
PCR testing will still be required, with antigen tests taking the pressure off the finite capacity i.e. not being used for asymptomatic patients (thereby making PCR testing more efficient in terms of turnaround times etc). Rapid testing backed up by PCR is the ultimate combination in my view.

The following provides another example of the route out, and the 'initial' phase of what indeed looks set to be a multibillion-dollar market in rapid antigen tests for COVID-19.

To directly purchase rapid antigen tests and deliver them to Member States, the Commission is mobilising €100 million under the Emergency Support Instrument. In parallel, the Commission is launching a joint procurement to ensure a second stream of access -

Press release28 October 2020
Brussels
Coronavirus resurgence: Commission steps up action to reinforce preparedness and response measures across the EU

2 - Establishing more effective and rapid testing

Testing is a decisive tool to slow down the spread of the coronavirus. To promote a common approach and effective testing, the Commission is today adopting a Recommendation on COVID-19 testing strategies, including the use of rapid antigen tests. It sets out key elements to be considered for national, regional or local testing strategies, such as their scope, priority groups, and key points linked to testing capacities and resources, and indications as to when rapid antigen testing may be appropriate. It also calls on Member States to submit national strategies on testing by mid-November. To directly purchase rapid antigen tests and deliver them to Member States, the Commission is mobilising €100 million under the Emergency Support Instrument. In parallel, the Commission is launching a joint procurement to ensure a second stream of access. Where Member States are applying prior testing requirements to incoming travellers and where no testing capacities are available for asymptomatic travellers in the country of origin, travellers should be offered the possibility to undergo a test after arrival. If negative COVID-19 tests are to be required or recommended for any activity, mutual recognition of tests is essential, in particular in the context of travel.

Full release -

wan
03/11/2020
17:16
From Lex column on FT website...



Eyes rolled when UK prime minister Boris Johnson first enthused about a “moonshot” mass testing programme. Scepticism remains. But there is a real chance wholesale screening for coronavirus, which begins in Liverpool this week, could help the UK economy reopen.

The tests, which detect tell-tale proteins known as antigens, are quick and cheap. They are not as accurate as tests that detect the virus’s genetic material. But they can spot people who are at greatest risk of spreading the disease.

The tests account for 60 per cent of the total in India. Slovakia used them to screen the bulk of its population last weekend. The World Health Organization plans to make 120m tests available to poorer countries.

There are risks. There are fears that India’s reliance on relatively inaccurate tests may misrepresent the disease’s severity. Daily screening using a test devised by US healthcare company Abbott — which correctly identifies Covid cases 95 per cent of the time — did not stop the outbreak in the White House last month. But conducted regularly enough, it could be a valuable tool.

That could create a big and possibly lucrative market. Stefan Hamill of Numis estimates the cost at £1 for a test selling for £5. For now at least, demand outstrips supply. Swiss drugmaker Roche said last week the market was “totally sold out” as it ramped up production of its rapid test, launched in partnership with South Korea’s SD Biosensor.

Not every test will make the grade. Only six out of 70 reviewed for the UK government impressed. It has inked contracts with the likes of Innova, owned by US-based investment company Pasaca Capital. Innovators may yet come up with improvements. Indian conglomerate Tata plans to launch a paper-based test that is said to be more accurate than antigen tests and nearly as quick.

Hopes of a return to normality have focused on vaccines. But their success is not guaranteed. That justifies a focus on mass testing. This could provide a vital route out of the crisis — and create a multibillion-dollar industry.

speedsgh
03/11/2020
10:34
Trellus looks quite interesting to me. EKF is a great lead in to Trellus happy to keep adding EKF in the hope of gaining Trellus

AIMHO
GLA
BTG

btgman
03/11/2020
09:47
It's worth checking Trellus news/coverage -



Including this one -

How Technology is Assisting Those With Chronic Conditions Amidst COVID
October 16, 2020

Typically, traditional care models for managing chronic conditions don’t address patients’ emotional well-being – which can be a painful and costly mistake. Patients with IBD and a mental health comorbidity drive three to five times higher annual healthcare costs, according to Monique Fayad, CEO of Trellus Health.

Fayad explains how technology is helping patients in these situations, especially during times of COVID-19.

“COVID-19 brought telehealth and resilience to the forefront of care,” Fayad says. “It amplified the need for telehealth and resilience-driven care for IBD patients due to their immunocompromised conditions, and the fact (that) they already struggled with physically getting to appointments because of their condition. Increased stress and anxiety due to COVID heightened awareness of the importance of behavioral health and resilience, and helped the entire healthcare system and patients understand the need for resilience-driven, whole-person care to improve outcomes and quality of life.”

“Trellus’s goal is to provide a technology platform to scale the co-founders’ whole-person approach globally to all chronic disease patients.”

She adds all partners in care can benefit from Trellus Health’s innovative resilience-driven connected health solution. For example, insurers can better track and manage their chronic disease patient populations via the TrellusElevate platform and the Trellus multidisciplinary care team’s convenient telehealth interactions, to significantly improve outcomes while reducing costs.

Full story -

They also have a new CTO -

wan
03/11/2020
09:41
The mid price for Verici is currently 34.5p, perhaps also demonstrating the level of demand. So, it will be interesting to see what EKF's ultimate holding amounts to.

I am a holder of the in-specie shares and a buyer of Verici (VRCI)!

wan
03/11/2020
08:30
Edit...'Routine' added to last post.
wan
03/11/2020
07:59
Wan had seen your 779 post looks like this is the start, as you say EKF involvement has yet to be clarified but a very small percentage will be a very big number.

AIMHO
GLA
BTG

btgman
03/11/2020
07:32
Btgman...I have been commenting on mass/public wide testing for a while now, because this also involves antigen tests, and the new PrimeStore ATM product (that EKF have already been trained for) apparently enhances/enables antigen testing!

See my post 779 where I also state -
Obviously, we don't yet know where the new ATM product will be deployed (apart from low-cost markets), but the dynamics are rapidly changing, and I stand by my previous view that ATM potentially has wide applicability across a range of antigen tests, and potentially specific utility in enabling antigen testing (for which interest in and global deployment is exploding).
(END)

The initial waves of mass testing are ripples, a tsunami of 'combined' routine testing looks set to follow!

wan
03/11/2020
07:18
Verici is admitted to AIM today with a £28.35m m/cap - the fundraising was "significantly oversubscribed", and EKF held 3.9% pre-admission (less now obviously):
rivaldo
03/11/2020
07:12
Half a million people in Liverpool will be tested every week for coronavirus whether or not they have symptoms in what ministers hope will be the first steps towards an exit strategy from the pandemic for the whole country.

Weekly tests ~I will be intrigued to hear Wan's thoughts around this. If this is to replicated worldwide test numbers are going to be off the scale.

AIMHO
GLA
BTG

btgman
03/11/2020
03:06
Also a report on the BBC saying..."The pilot will start this week and will include a mix of existing swab tests and new lateral flow tests, which can provide a result within an hour without the need to use a lab."
lastoneout
03/11/2020
02:18
Moonshot pilot kicking off in Liverpool https://inews.co.uk/news/politics/coronavirus-latest-game-changing-rapid-test-trial-liverpool-explained-746265
lastoneout
02/11/2020
16:29
Sure thing - this could go all the way to £3 if Mr Market decides on a more generous multiple for the business but the target number does not mean much to me. For me, it’s far more relevant how does one get there. In other words, I try to avoid major bumps along the road as I am not willing to tolerate more than 10-12% drawdowns on my way to Valhalla. Like I said - I employ a different method.
tongosti
02/11/2020
14:15
Tongosti

I take both a long term and short term view it is currently difficult to predict 2021 without the update but fair to say I expect it to be significantly above EPS of 5p I would think towards double this number at which point £2 comes in to play. £1 is just a number based around 2020 EPS I rather prefer the look of £2 a year or so out if not before.

INMHO
GLA
BTG

btgman
02/11/2020
14:03
Btgman - I agree with you on the fundamental front. This is indeed a very sound business (I take it you take a longer term approach which is of course fine but is entirely different from my own game). Whilst the underlying story is great, the share price is severely overextended (statistically), by my own calculations. As this is a game of odds, I have a particular way to play it. Pros and cons to everything of course but one sticks with one's rules. I have still 2/3 of my original position on but if we have another violent eruption North in very quick order (amen to that I hear you say) then I will probably sell it all and patiently wait for the next next point of reentry. Thanks and good luck - let's hope we reach that magical 100 quote soon!
tongosti
02/11/2020
13:23
Never bad to take a profit Tongosti. However, with the exponential growth worldwide regards testing I have a view that EKF has a very long way to go. I am intrigued to hear the trading update and the out look for 2021 has to be even stronger. This could still double and some in quick time from here I am still of a view of EPS of 5p plus for y.e 31.12.20 at which point it looks cheap with underlying asset position and all the testing. What is also apparent if you search EKF and key last hour amazing how many time it comes up related to other products

AIMHO
GLA
BTG

btgman
02/11/2020
12:55
After an amazing run over the last couple of weeks decided to to slice and sell a third into current strength.
tongosti
02/11/2020
10:08
Spread was 74 vs 77 when I posted.
eeza
02/11/2020
10:03
Don't think so - spreads are as tight as they've been for a good few days. You have a lot of demand today as well as volumes indicate. Past 85, 100p is very probably next. Onwards and upwards EKF!
tongosti
02/11/2020
09:07
MM's opened the spread to try to damp the buying.
eeza
02/11/2020
09:06
Another great start of the day. About +25% in less than two weeks. In the context of wider markets this is an absolute delight.
tongosti
01/11/2020
12:13
Unfortunately the dynamics of the pandemic have obviously changed, so one has to ask has this also influenced where and particularly when new rapid tests are deployed? I think it has!

By my estimates the UK government has purchased circa 10m of Abbotts PANBIO™ COVID-19 Ag RAPID TEST DEVICE that I highlighted in post 758. That's quite a lot more, in terms of units, than some of the other tests that have been ordered (at a price of around £4 per unit, see further below).


But overall, the range and availability of tests are expanding rapidly, and other new tests, including rapid test (preferably domestically manufactured), and the required ramp in manufacturing capacity are going to be required beyond the current lockdown and 'first wave' of mass UK testing!

I also highlighted in post 758 and 759 that low cost settings and low cost markets can be one of the same in terms of a cheap point of care device. EKF have already stated that the ATM product aimed at low cost markets expected Q4, and obviously we are in Q4. But as I mention above, and as evidenced here in the UK, the dynamics have changed with cheap lateral flow tests also being deployed (and indeed required) in developed markets!

Back to low-cost setting/markets. The following was what originally caught my attention in terms of being particularly interested in low cost tests and in particular Abbotts PANBIO test, and why it's possible for investors to feel somewhat better from benefitting from the pandemic (hopefully, one way or another, that will include investors in EKF). The initial roll-out of the tests were scheduled for October. It's a very worthy read for all investors -

Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries
28 September 2020


I think the reason Abbotts PANBIO test has been somewhat off the radar, is that it was developed/manufactured by their German subsidiary - Abbott Rapid Diagnostics Jena GmbH (which might have originally been part of Alere). As up until very recently it had not made Abbotts main news, and Abbott's main site only listed one antigen test, and that wasn't PANBIO!

After completion of the development stage, the site oversees the transfer to mass production; the products are marketed through the global sales network of the Abbott group.


Obviously, we don't yet know where the new ATM product will be deployed (apart from low-cost markets), but the dynamics are rapidly changing, and I stand by my previous view that ATM potentially has wide applicability across a range of antigen tests, and potentially specific utility in enabling antigen testing (for which interest in and global deployment is exploding).

And to repeat an important point (none of us, to my knowledge, are experts!) - Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.

wan
31/10/2020
20:03
Quick update -

Gary Dowthwaite
Special Projects Coordinator at EKF Diagnostics
11 hours ago
It all starts with the pooled sample.

Luke Daum
Chief Scientific Officer and Executive VP at Longhorn Vaccines and Diagnostics
17m

Gary, you're correct. Incidentally, the clinical specimens used in this small study were derived from EKF staff-critical personnel-that we at Longhorn are committed to ensuring remain healthy as we all work in collaboration to maintain PrimeStore MTM supply chains worldwide. Longhorn/EKF synergy in the fight against Covid19.

wan
31/10/2020
20:03
Yippee!!!

Oops, sorry, shamefaced emoji...

supernumerary
Chat Pages: Latest  98  97  96  95  94  93  92  91  90  89  88  87  Older

Your Recent History

Delayed Upgrade Clock